Temozolomida en el tratamiento de gliomas malignos
- Marta Manso Manrique
- Angel Sánchez
- Carlos Folguera Olias
- P. Calabuig Fernández
- Elena García Sanz
ISSN: 1139-7357
Argitalpen urtea: 2004
Alea: 6
Zenbakia: 5
Orrialdeak: 312-318
Mota: Artikulua
Beste argitalpen batzuk: Atención Farmacéutica
Laburpena
Temozolomide is prescribed for the treatment of malignant glioma. We attempt to analyze its use in the Puerta de Hierro University Hospital, by evaluating its efficacy, tolerance and cost. Out of the 23 patients treated with temozolomide, after 6 months under treatment, 7.69% presented a partial response, 22.91% stabilization and 69.4% suffered from a disease progression. Survival free from any disease progression after 6 months was of 30.77% and after a year of 23.08%. Global survival after 6 months was of 61.54% and after a year 46.15%. 43.48% of patients presented good tolerance, 21.74% minor vomit or nausea and 30.43% hematologic toxicity. In conclusion, the use of temozolomide seems to be justified because of its oral administration and good tolerance, along with minor periods of absence of tumoral growth and of global survival increase